HomeAI · summaries
Storia in 2 fonti
New First-Line Option Approved in Triple-Negative Breast Cancer
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC
AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.
- ·
medpagetoday.com
New First-Line Option Approved in Triple-Negative Breast Cancer
Datopotamab deruxtecan indicated for patients ineligible for immunotherapy